Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused ...
Millendo Therapeutics is a late-stage biopharma...
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing...
Ovid Therapeutics is a biopharmaceutical compan...
Aptose Biosciences is a clinical-stage biotechnology company developing personaliz...
Aptose Biosciences is a clinical-stage biotechn...
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses o...
Aeolus Pharmaceuticals, Inc. is a biopharmaceut...
For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...
For more than 40 years, IntriCon has been meeti...
Abeona Therapeutics is focused on developing and delivering gene therapy products ...
Abeona Therapeutics is focused on developing an...
Myriad Genetics, Inc., is a leading precision medicine company dedicated to being ...
Myriad Genetics, Inc., is a leading precision m...
Founded in 1987, Merit Medical set out to build the worldâs most customer-focuse...
Founded in 1987, Merit Medical set out to build...
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
Join the National Investor Network and get the latest information with your interests in mind.